MX2022010950A - Compuesto triciclico fusionado y uso farmaceutico del mismo. - Google Patents
Compuesto triciclico fusionado y uso farmaceutico del mismo.Info
- Publication number
- MX2022010950A MX2022010950A MX2022010950A MX2022010950A MX2022010950A MX 2022010950 A MX2022010950 A MX 2022010950A MX 2022010950 A MX2022010950 A MX 2022010950A MX 2022010950 A MX2022010950 A MX 2022010950A MX 2022010950 A MX2022010950 A MX 2022010950A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- disease
- heart failure
- retinopathy
- diabetic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 101100463130 Arabidopsis thaliana PDK gene Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 abstract 1
- 208000005018 Hyperlactatemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 208000012268 mitochondrial disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
Abstract
La presente invención proporciona un compuesto que tiene un inhibidor de actividad de PDHK y útil para el tratamiento o profilaxis de diabetes (diabetes tipo 1, diabetes tipo 2 etc.), síndrome de resistencia a la insulina, síndrome metabólico, hiperglucemia, hiperlactacidemia, complicación diabéticas (neuropatía diabética, retinopatía diabética, nefropatía diabética, catarata etc.), insuficiencia cardíaca (insuficiencia cardíaca aguda, insuficiencia cardíaca crónica), miocardiopatía, isquemia de miocardio, infarto de miocardio, angina de pecho, dislipidemia, aterosclerosis, enfermedad de las arterias periféricas, claudicación intermitente, enfermedad pulmonar obstructiva crónica s, isquemia cerebral, apoplejía cerebral, enfermedad mitocondrial, encefalomiopatía mitocondrial, cáncer, hipertensión pulmonar, enfermedad de Alzheimer, demencia vascular, glaucoma, retinopatía diabética, retinopatía del prematuro, oclusión de la vena retiniana, neuropatía óptica isquémica o enfermedad renal crónica. La presente invención se refiere a un compuesto de la fórmula [I-a], o una de sus sales farmacéuticamente aceptables: (ver Fórmula) en donde cada símbolo es como se define en la DESCRIPCIÓN.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020036931 | 2020-03-04 | ||
JP2021001452 | 2021-01-07 | ||
PCT/JP2021/008055 WO2021177330A1 (ja) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及びその医薬用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010950A true MX2022010950A (es) | 2022-10-07 |
Family
ID=77613417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010950A MX2022010950A (es) | 2020-03-04 | 2021-03-03 | Compuesto triciclico fusionado y uso farmaceutico del mismo. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230025880A1 (es) |
EP (1) | EP4116301A4 (es) |
JP (1) | JP2022007994A (es) |
KR (1) | KR20220149688A (es) |
CN (1) | CN115151543A (es) |
AU (1) | AU2021230880A1 (es) |
BR (1) | BR112022014749A2 (es) |
CA (1) | CA3166747A1 (es) |
CL (1) | CL2022002355A1 (es) |
CO (1) | CO2022012548A2 (es) |
IL (1) | IL295836A (es) |
MX (1) | MX2022010950A (es) |
PE (1) | PE20221908A1 (es) |
TW (1) | TW202146410A (es) |
WO (1) | WO2021177330A1 (es) |
ZA (1) | ZA202209620B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200115566A (ko) * | 2018-02-01 | 2020-10-07 | 니뽄 다바코 산교 가부시키가이샤 | 질소 함유 복소환 아미드 화합물 및 그의 의약 용도 |
AR126913A1 (es) * | 2021-09-01 | 2023-11-29 | Japan Tobacco Inc | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1615647B1 (en) * | 2003-04-11 | 2010-01-20 | High Point Pharmaceuticals, LLC | Pharmaceutical use of fused 1,2,4-triazoles |
US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
CA2904985C (en) * | 2013-03-15 | 2021-07-20 | Japan Tobacco Inc. | Pyrazole-amide compound and medicinal uses therefor |
CN107849042B (zh) * | 2015-07-31 | 2021-04-13 | 默克专利股份公司 | 双环杂环衍生物 |
KR20200115566A (ko) * | 2018-02-01 | 2020-10-07 | 니뽄 다바코 산교 가부시키가이샤 | 질소 함유 복소환 아미드 화합물 및 그의 의약 용도 |
CN112638377A (zh) | 2018-09-11 | 2021-04-09 | 日本烟草产业株式会社 | 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂 |
-
2021
- 2021-03-03 MX MX2022010950A patent/MX2022010950A/es unknown
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko unknown
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 EP EP21764169.5A patent/EP4116301A4/en active Pending
- 2021-03-03 JP JP2021033150A patent/JP2022007994A/ja active Pending
- 2021-03-03 CN CN202180018517.1A patent/CN115151543A/zh active Pending
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja active Application Filing
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 IL IL295836A patent/IL295836A/en unknown
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 AU AU2021230880A patent/AU2021230880A1/en active Pending
- 2021-03-03 TW TW110107548A patent/TW202146410A/zh unknown
-
2022
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4116301A4 (en) | 2024-04-03 |
IL295836A (en) | 2022-10-01 |
BR112022014749A2 (pt) | 2022-10-11 |
EP4116301A1 (en) | 2023-01-11 |
TW202146410A (zh) | 2021-12-16 |
JP2022007994A (ja) | 2022-01-13 |
CO2022012548A2 (es) | 2022-09-20 |
AU2021230880A1 (en) | 2022-09-29 |
CA3166747A1 (en) | 2021-09-10 |
KR20220149688A (ko) | 2022-11-08 |
US20230025880A1 (en) | 2023-01-26 |
CN115151543A (zh) | 2022-10-04 |
WO2021177330A1 (ja) | 2021-09-10 |
CL2022002355A1 (es) | 2023-03-03 |
ZA202209620B (en) | 2023-12-20 |
PE20221908A1 (es) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202209620B (en) | Fused tricyclic compound and medicinal use thereof | |
PH12020500613A1 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
CO2024003629A2 (es) | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico | |
DK2114934T3 (en) | COMPOSITION AND METHODS FOR MODULATING A kinase cascade | |
JP2019131544A5 (es) | ||
EP1385820B1 (de) | Anthranilsäureamide, verfahren zu ihrer herstellung, ihre verwendung als antiarrhythmika sowie pharmazeutische zubereitungen davon | |
JP7067792B2 (ja) | 新たなピラジン誘導体及びその調製方法並びに医薬応用 | |
DK2155681T3 (en) | PROCEDURE FOR PREPARING COMPOSITIONS FOR MODULATING CHINESE CASH AND METHODS FOR USING IT | |
CA2328396C (en) | New substituted amides, their production and their use | |
JP2015524443A5 (es) | ||
WO2011118672A1 (ja) | 血漿カリクレイン阻害剤 | |
JP2011508775A5 (es) | ||
US9499467B2 (en) | Ortho-fluoro substituted compounds for the treatment of metabolic diseases | |
JP2022007994A5 (es) | ||
CA3101977C (en) | Novel hif-1-alpha inhibitor, method of preparing the same, and pharmaceutical composition for preventing or treating angiogenesis-related eye disease containing the same as active ingredient | |
JPS62267270A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
WO2017016523A1 (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
CA2717537A1 (en) | 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents | |
CN109988131A (zh) | 盐酸胺碘酮的制备方法 | |
AU7911487A (en) | Resolution of dl-methyl 3-(4-(2-hydroxy-3-isopropylamino) propoxy)phenylpropionate((dl-esmolol)) | |
KR102176621B1 (ko) | 페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2001000601A1 (de) | 4-(2-oxodihydrooxadiazinylphenyl)amide und ihre verwendung zur bekämpfung von anämien | |
CN116947818B (zh) | 一种氧代吡啶类化合物、中间体及其制备方法和用途 | |
WO2009048274A3 (en) | Benzofuran and benzothiophene derivatives substituted with amide, process for the preparation thereof, and pharmaceutical compositions containing the same | |
Ding et al. | Preoperative aspirin and major perioperative outcomes in patients with hypertension undergoing cardiac surgery |